Key Points for Decision Makers {#FPar1}
==============================

Lower absolute willingness-to-pay and life expectancy are two important issues that can affect conclusions regarding the cost effectiveness of treatment in middle-income countriesAlthough most clinical guidelines worldwide recommend 1 year of trastuzumab for early human epidermal growth factor receptor 2 (HER2)-positive breast cancer, it is not the most cost-effective strategy in Iran.In Iran, the most cost-effective strategy is 6 months of trastuzumab, but only for patients younger than 59 years of age.A significant price reduction is necessary to make trastuzumab cost effective for all patients.

Introduction {#Sec1}
============

Trastuzumab is a monoclonal antibody that is used in the management of breast cancer (BC). It has mostly been used as adjuvant treatment for patients in the early stage of BC who overexpress human epidermal growth factor receptor 2 (HER2). Trastuzumab's huge share of total drug expenditure, particularly in middle-income countries (MICs), has raised concerns among policymakers regarding efficient resource allocation in their countries \[[@CR1]\]. To date, 1 year of trastuzumab use is considered as the optimum duration of therapy for the adjuvant treatment of early-stage, HER2-positive BC \[[@CR2]--[@CR4]\], based on the results of various randomized controlled trials (RCTs).

As an MIC, Iran provided a national guideline that recommends a 9-week period of trastuzumab use \[[@CR5]\] due to the unaffordability of 1 year of trastuzumab therapy \[[@CR1]\]; however, clinical evidence suggests that very short durations of trastuzumab therapy cannot provide significant efficacy \[[@CR2]\]. Therefore, the main question in this regard is "What is the maximum obtainable level of health in an MIC when we are dealing with an expensive intervention?"

The aim of this study was to provide a model-based cost-effectiveness analysis (CEA) of adjuvant trastuzumab for patients with early HER2-positive BC from an Iranian healthcare perspective. Subsequently, we undertake a scenario analysis to determine the optimum duration of trastuzumab use in Iran.

Methods {#Sec2}
=======

In our study, we compared two treatment approaches (chemotherapy with and without trastuzumab) for managing early HER2-positive BC. A Markov model was used to estimate the marginal differences in clinical outcomes and healthcare costs. We designed a cohort for patients with HER2-positive BC and included the necessary information in this model to estimate the incremental cost-effectiveness ratio (ICER) of using trastuzumab for these patients with a lifetime horizon in Iran. Afterward, a scenario analysis was conducted to compare the cost effectiveness of different strategies of trastuzumab therapy in an MIC.

Model Structure {#Sec3}
---------------

We designed a model structure based on three sources of information (Fig. [1](#Fig1){ref-type="fig"}). First, the routine practice of treating HER2-positive BC in Iran was understood based on a previous study of clinical practice using a claims database and clinician survey \[[@CR1]\]. We then discussed our interpretations of the results through a number of interviews with two Iranian academic oncologists, and based on our final decision on data availability. The model was designed to be able to compare two main arms (trastuzumab versus no trastuzumab), and included six main health states: (1) early BC; (2) loco-recurrence BC; (3) advanced BC; (4, 5) two progression-free health states after treatment in early BC and loco-recurrence BC; and (6) death. We also included other health-state subgroups for loco-recurrence (loco-regional and second primary BC), and advanced patients (central nervous system \[CNS\], visceral, bone, and soft tissue metastasis). Moreover, we incorporated long-term cardiotoxicity in all states in which patients use trastuzumab. A 3-month cycle length was used in the model \[[@CR1]\].Fig. 1Summary model structure. *BC* breast cancer, *HER2* human epidermal growth factor receptor 2, *CNS* central nervous system

In the model, patients with early HER2-positive BC received chemotherapy with or without trastuzumab. After treatment, patients moved to a follow-up state and could progress to local or advanced BC. Patients stayed in the follow-up state until the occurrence of progression (local or distance recurrence) or second primary BC. We assumed that patients in both arms were equally likely to receive all other medical services. Patients who had progressed to loco-recurrence after receiving the treatment could move to the disease-free state after the local-recurrence state, or progress to advanced BC; patients who progressed to advanced BC stayed there until they died from BC or other causes. Some of the patients who received trastuzumab developed reversible cardiac toxicity. Patients in all health states could die due to background mortality.

Patient Characteristics {#Sec4}
-----------------------

We set the age at onset of treatment at 45 years, in accordance with the results of a variety of current claims database \[[@CR6]\] and epidemiological \[[@CR7]--[@CR9]\] studies in Iran.

Transition Probabilities {#Sec5}
------------------------

The following items describe the input parameters used in the model as well as their sources. Various transition probabilities used in the model are shown in Table [1](#Tab1){ref-type="table"}.Table 1Transition probabilitiesParameterBase-case estimateDistributionDistribution parametersSource**Trastuzumab effectiveness**DFS trastuzumab HR (12 m versus 0 m)0.62Log-normal*µ* = −0.49, *σ* = 0.13Moja et al. \[[@CR2]\]DFS trastuzumab HR (6 m versus 12 m)1.28Log-normal*µ* = 0.23, *σ* = 0.16Pivot et al. \[[@CR3]\]DFS trastuzumab HR (9 m versus 12 m)1.14Log-normal*µ* = 0.13, *σ* = 0.08AssumptionTreatment effect duration48 mLog-normal*µ* = 3.87, *σ* = 0.307Hall et al. \[[@CR10]\]**Disease progression**Recurrence without trastuzumab Months 1--480.28Beta*α* = 472, *β* = 1226Gianni et al. \[[@CR12]\] Months 49--600.23Beta*α* = 35, *β* = 116Paik et al. \[[@CR13]\] Months 61--1200.10Beta*α* = 11, *β* = 94 Beyond 120 months0FixedExpert opinionLoco versus distant recurrences Without trastuzumab0.355Beta*α* = 100, *β* = 182Gianni et al. \[[@CR12]\] With trastuzumab0.372Beta*α* = 79, *β* = 133Distance recurrence pattern Without trastuzumab  Bone0.25Dirichlet*α*1 = 38Piccart-Gebhart et al. \[[@CR16]\]  Soft tissue0.12*α*2 = 19  Visceral0.53*α*3 = 82  CNS0.10*α*4 = 15 With trastuzumab  Bone0.28Dirichlet*α*1 = 24Piccart-Gebhart et al. \[[@CR16]\]  Soft tissue0.07*α*2 = 6  Visceral0.40*α*3 = 34  CNS0.25*α*4 = 21Second primary or contralateral breast cancer Years 1--40.019Beta*α* = 33, *β* = 1698Gianni et al. \[[@CR12]\] Years 5--100.026Beta*α* = 10, *β* = 359Metzger-Filho et al. \[[@CR48]\]Increased risk of distant metastasis after local recurrence (HR) Years 1--43.22Log-normal*µ* = 1.16, *σ* = 0.14Tanis et al. \[[@CR17]\] Years 5--106.14Log-normal*µ* = 1.68, *σ* = 0.52**Cardiac toxicity**Trastuzumab-induced decline in LVEF0.112Beta*α* = 466, *β* = 4147Moja et al. \[[@CR2]\]Trastuzumab-induced CHF0.025Beta*α* = 135, *β* = 5471CHF due to chemotherapies0.004Beta*α* = 20, *β* = 4810Duration of reversible cardiac toxicity3 monthsFixedSuter et al. \[[@CR18]\]Time of onset during treatment3--6 monthsDirichlet*α*s = 8, 69, 14, 27Population background level of CHF among Iranian femalesAge-specificNormalTalaei et al. \[[@CR19]\]**Mortality**Background mortality for Iranian femalesAge specificFixedNOfCR\[[@CR20]\]Breast cancer-specific mortality for Iranian femalesAge specificFixedVostakolaei et al. \[[@CR7]\]Mortality from heart failure for Iranian females (1 year, age-adjusted)0.263Beta*α* = 727, *β* = 2042Talaei et al. \[[@CR19]\]Mortality due to metastatic BC Bone (over 5 years)0.63Beta*α* = 17, *β* = 10Dawood et al. \[[@CR49]\] Soft tissue (over 5 years)0.77Beta*α* = 12, *β* = 4 Visceral (over 5 years)0.78Beta*α* = 28, *β* = 8 Brain (over 9 months)0.50Beta*α* = 54, *β* = 54Niwinska et al. \[[@CR50]\]*CHF* congestive heart failure, *DFS* disease-free survival, *LVEF* left ventricular ejection fraction, *m* months, *HR* hazard ratio, *CNS* central nervous system, *BC* breast cancer

### Treatment Effect {#Sec6}

The effectiveness of trastuzumab was derived from a Cochrane review \[[@CR2]\] that was a comprehensive systematic review and meta-analysis of eight RCTs regarding disease-free survival (DFS) of trastuzumab. Due to our study design, we relied on a DFS hazard ratio (HR) based on the results of the meta-analysis of those trials (five of eight) that investigated the effects of more than 6 months of trastuzumab therapy. To include the treatment effect duration in the model, we used an assumption that was used in a CEA of trastuzumab in the UK \[[@CR10]\], based on discussions with experts.

### Cancer Progression {#Sec7}

For the first 4 years, the recurrence rate in the 'no trastuzumab' arm was obtained from the latest HERceptin Adjuvant (HERA) trial \[[@CR11]\] report after a 4-year patient follow-up \[[@CR12]\]. For years 5--10, the recurrence rates were taken from the anthracycline-treated HER2-positive subgroup of the National Surgical Adjuvant Breast and Bowel Project (NSABP) protocol B-15 trial \[[@CR13]\]. Since that trial only focused on lymph node-positive patients, we applied a relative risk of 0.815 based on a study reporting that 63% of Iranian patients have node-positive BC at the time of diagnosis \[[@CR14]\], and the assumption that node-positive patients have a recurrence rate that is two times greater than node-negative patients \[[@CR15]\]. We also assumed no chance of recurrence after 10 years based on expert opinion. The ratio of loco-recurrences to distant recurrences was obtained from the results of the HERA trial \[[@CR16]\]. Two HRs were applied to represent the increased risk of distant metastases after local recurrence. These HRs were 3.22 (95% confidence interval \[CI\] 2.02--6.55) and 6.14 (95% CI 2.02--6.55) for years 1--4 and 5--10, respectively \[[@CR17]\].

### Cardiac Toxicity {#Sec8}

The results of a Cochrane systematic review and meta-analysis \[[@CR2]\] were used to estimate the probabilities of decline in left ventricular ejection fraction (LVEF) and congestive heart failure (CHF) occurring during 1 year of trastuzumab therapy and other chemotherapy drugs. The time of onset and toxicity duration for patients who had reversible cardiac toxicity were taken from the HERA trial \[[@CR18]\]. Moreover, patients suffer from CHF based on an age-specific background, and these probabilities were obtained from a cohort study of 6504 individuals in one province of Iran \[[@CR19]\].

### Mortality {#Sec9}

Age-specific background mortality rates were obtained from online data of the National Organization for Civil Registration (NOCR) \[[@CR20]\], which included data on all causes of death in Iran. We used another study of BC mortality rates in three different age ranges \[[@CR7]\] to subtract the BC mortality rate from the NOCR data. Data on the age-specific CHF mortality rate in Iran was obtained from an Iranian cohort study \[[@CR19]\]. Other parameters regarding BC mortality rates in various metastatic states were extracted from international studies.

Outcomes {#Sec10}
--------

Life-years (LYs) and quality-adjusted life-years (QALYs) were estimated for both arms. Table [2](#Tab2){ref-type="table"} shows the utility values used in this study. We used the results of a study that provided the utility weights for various health states, based on the EQ-5D questionnaire in Sweden \[[@CR21]\]. Another study that used the EQ-5D was selected to find the utility weight for patients who suffer from symptomatic heart failure in the UK \[[@CR22]\]. Finally, the utility value (EQ-5D) for patients with brain metastases was obtained from a CEA study in the UK \[[@CR10]\].Table 2Utilities and costs (year 2017)ParameterMeanStandard errorDistributionSource**Health utilities**Baseline (disease-free)0.7790.017BetaLidgren et al. \[[@CR21]\]Treatment of early stage0.7790.017BetaAssumptionSymptomatic cardiac toxicity0.6000.010BetaCalvert et al. \[[@CR22]\]Loco-recurrence0.7800.040BetaLidgren et al. \[[@CR21]\]Second primary breast cancer (first year)0.7000.032BetaAdvanced (bone, visceral and soft tissue)0.6900.033BetaAdvanced (brain)0.6000.120BetaHall et al. \[[@CR10]\]**Costs (€) \[€1** **=** **34,000 rilas\]**Treatment Trastuzumab (first cycle)6123FixedSSO \[[@CR51]\] Trastuzumab (second, third, and fourth cycles)5623Fixed Early treatment first year3689245Log-normalAnsaripour et al. \[[@CR6]\] Trastuzumab administration (6 months)^a^188194Log-normal Trastuzumab administration (9 months)^a^329359Log-normal Trastuzumab administration (1 year)^a^471485Log-normal Follow-up annual cost37034Log-normalCardiac toxicity Symptomatic heart failure annual cost584140Log-normalAnsaripour et al. \[[@CR6]\]Cancer recurrence costs Second primary breast cancer first year6024228Log-normalAnsaripour et al. \[[@CR6]\] Second primary breast cancer annual costAs follow-up annual costLog-normalAssumption Loco-recurrence first year3922177Log-normalAnsaripour et al. \[[@CR6]\] Loco-recurrence annual cost2238357Log-normal Advanced treatment first year18,1511394Log-normal Advanced treatment annual cost83,2492027Log-normal^a^ The cost of trastuzumab administration in the first 9 weeks is excluded here due to administration of trastuzumab with other chemotherapy drugs in the same sessions. The cost of trastuzumab administration in the first 9 weeks is included in the cost of early treatment in the first year

Costs {#Sec11}
-----

Direct medical costs were calculated from an Iranian healthcare perspective. We assumed 100% coverage for all healthcare services by payers, which helps policymakers to examine the cost effectiveness of complete coverage of all services. We used a recent study that investigated healthcare costs and resource use in both the public and private sectors in Iran, which covers approximately 50% of all Iranians (approximately 40 million) \[[@CR6]\]. Due to the variety of health insurance coverage in Iran \[[@CR23]\], out-of-pocket payments had already been included in cost calculations \[[@CR6]\]; therefore, the costs shown in Table [2](#Tab2){ref-type="table"} comprise the total costs of medical services. The average patient weight must be known to calculate the cost of trastuzumab; therefore, we used data from a 3-year observational period \[[@CR1]\] to estimate the average weight based on the average dose of trastuzumab per patient using trastuzumab. The average dose per patient per prescription was 420 mg (95% CI 415--424; *n* = 1295), which corresponds with an average weight of 70 kg (69--71). While this may not represent the true average weight of the patients, in reality these real-world data represent the total amounts of trastuzumab, both used and wasted. Patients received trastuzumab in a 3-week cycle until the end of therapy.

The annual national healthcare tariff \[[@CR24]\] was used to inflate or adjust the costs attained from years other than the 2014--2017 values.

Analysis {#Sec12}
--------

In the absence of a national guideline for economic evaluations in Iran, both costs and effects were discounted by 3.5% per annum, as suggested by the World Health Organization's Choosing Interventions that are cost-effective (WHO-CHOICE) project \[[@CR25]\]. A half-cycle correction was also applied.

The influence of specific input parameters on the ICER of CEA was examined using deterministic sensitivity analysis (DSA). The ranges in values were determined based on either the literature or on expert opinion.

A probabilistic sensitivity analysis (PSA) was performed in order to quantify the overall uncertainty in the expected output measures \[[@CR26], [@CR27]\]. The log-normal distribution was applied for relative risks, HRs, and costs, while the Dirichlet distribution was used for multinomial proportions and the beta distribution was used for binomial proportions and utility weights. The analysis used 10,000 iterations obtained via Markov Chain Monte Carlo simulation.

Based on the WHO-CHOICE, the willingness-to-pay (WTP) threshold in Iran would be 3 × gross domestic product (GDP)/capita, which is equal to €21,000 per QALY (€1 = 34,000 rials) \[[@CR28]\]. Because widespread international economic sanctions on Iran began in 2012, we used GDP per capita in 2011, as reported by the World Bank \[[@CR29]\], to avoid the effects of these sanctions on Iran's GDP.

The building of the model, calculations, and statistical analysis were performed using R software for Microsoft Windows, version 3.2.2 (The R Project, Vienna, Austria) \[[@CR30]\].

Estimation of the Optimum Duration and Maximum Age Threshold for Trastuzumab Use {#Sec13}
--------------------------------------------------------------------------------

Three scenarios of 6, 9 months, and 1 year of trastuzumab use were designed to compare their cost effectiveness. We used the results of the randomized, non-inferiority PHARE trial \[[@CR3]\], which compared 6 months versus 1 year of adjuvant trastuzumab therapy, and the results of a Cochrane meta-analysis \[[@CR2]\], which compared 1 year of trastuzumab versus no trastuzumab therapy. For 9 months of trastuzumab use, we assumed that the effectiveness HR was half of the non-inferiority HR in the PHARE trial (Table [1](#Tab1){ref-type="table"}). The ICERs of the three strategies were calculated and, eventually, their probability of being cost effective was compared with that of the no trastuzumab arm. Furthermore, due to the importance of patient age, we investigated how the age threshold for treatment can affect the optimal duration of trastuzumab use. Multiple PSAs were performed, with various ages (40--70 years) as the age at onset of treatment, to determine the 'maximum age threshold' for the best-case scenario. The 'maximum age threshold' represents the maximum age at the onset of treatment that still results in the strategy being optimal, versus other strategies included in the comparison at a particular WTP threshold.

Model Validation {#Sec14}
----------------

Internal validation was performed to assess how well the model's results for DFS and overall survival (OS) corresponded with the no trastuzumab and 1-year trastuzumab arms from the HERA trial. Similarly, the results of the PHARE trial were used to validate the model's results for the 1-year and 6-month trastuzumab strategies.

Results {#Sec15}
=======

Over a lifetime horizon, all trastuzumab strategies were cost effective versus no trastuzumab at a WTP of 3 × GDP (Fig. [2](#Fig2){ref-type="fig"}). The results of CEA, reported in Table [3](#Tab3){ref-type="table"}, show that at the WTP threshold of 3 × GDP, and a 42% probability, the 6-month protocol was the most cost-effective strategy, while other strategies showed lower rates of being cost effective. The acceptability curves representing the probabilities that various strategies are cost effective across various WTP thresholds in the base-case scenario can be found in Fig. [3](#Fig3){ref-type="fig"}. The 1-year trastuzumab strategy was cost effective in only 21% of simulations, and the 9-month and no trastuzumab strategies were cost effective in 21 and 17% of cases, respectively. When the WTP threshold was increased to 4 × GDP, the 6-month and 1-year regimens were essentially equal in cost effectiveness (37 and 35%, respectively). The 9-month regimen had a 20% probability of cost effectiveness. However, the chance of the no trastuzumab strategy being cost effective fell to 8% when a WTP threshold of 4 × GDP was applied.Fig. 2Cost-effectiveness plan for trastuzumab use scenarios versus no trastuzumab (a sample of 7000 results of PSA for every strategy). The ellipses represent 95% confidence intervals. *GDP* gross domestic product, *QALYs* quality-adjusted life-years, *PSA* probabilistic sensitivity analysis Table 3Results of the cost-effectiveness analysisStrategiesCost (€)QALYsLYsICER (QALY)ICER (LY)No trastuzumab14,54111.114.41NANA6 months of trastuzumab22,44211.7115.1814,62511,664*Δ* = 8901*Δ* = 0.61*Δ* = 0.769 months of trastuzumab28,41011.9515.4816,37013,037*Δ* = 13,869*Δ* = 0.85*Δ* = 1.061 year of trastuzumab33,16012.2215.8216,69513,279*Δ* = 18,619*Δ* = 1.12*Δ* = 1.40*Δ *= incremental values for costs and effectiveness of trastuzumab therapy strategists versus no trastuzumab*QALYs* quality-adjusted life-years, *LYs* life-years, *ICER* incremental cost-effectiveness ratio, *NA* not applicable Fig. 3Acceptability curves of the base-case scenario. *GDP* gross domestic product

The base-case and DSA of the model yields ICERs for 6, 9 months and 1 year of €15,108, €16,800, and €17,086 per QALY versus no trastuzumab, respectively. Subsequently, deterministic one-way sensitivity analysis (summarized in Table [4](#Tab4){ref-type="table"}) revealed that the key drivers were the acquisition cost and clinical effectiveness of 1 year of trastuzumab use versus no trastuzumab. Additionally, probabilistic one-way sensitivity analysis showed that when the cost of trastuzumab was changed from −30 to +30% in the base-case, the probability of the 1-year regimen being cost effective decreased from 41 to 8% (Online Resource 1). However, 6 months of trastuzumab therapy showed less of a change (9; 34--43%) at a threshold of 3 × GDP. In contrast, changes in the HR of DFS for 6 months of trastuzumab use versus no trastuzumab showed a range of 16% (54--38%) in the lower (0.50) and upper (0.74) limits (Online Resource 2). At a threshold of 3 × GDP, the 6-month regimen was the most cost-effective strategy (54%) for the lower limit of HR, and the no trastuzumab strategy was the cost-effective strategy for the upper limit of HR. Finally, our results (Fig. [4](#Fig4){ref-type="fig"}) show that the 6-month strategy is only cost effective when treated patients are not older than 59 years (the maximum age threshold). At this age, and at a WTP threshold of 3 × GDP, the two strategies of 6 months of trastuzumab and no trastuzumab had almost equal chances of being cost effective (39.5 versus 40%, respectively). However, this age threshold can change if the WTP is increased or decreased. At the WTP threshold of 4 × GDP, 1 year of trastuzumab use is only cost effective for patients who are younger than 44 years, and 6 months of trastuzumab use may be the best strategy for patients between 44 and 66 years of age (Online Resource 3). Finally, the impact of various ages (40--70 years) on the cost effectiveness of different strategies are shown in Online Resource 4.Table 4Results of one-way deterministic sensitivity analysis; the impact of the top seven key drivers on the incremental cost-effectiveness ratioBase-caseLimitsValueReferenceStrategiesNo trastuzumab6-month trastuzumab9-month trastuzumab1-year trastuzumabCost changesQALY changesLY changesCost/QALYs changesCost/LY changesCost/QALYs changesCost/LY changesCost/QALYs changesCost/LY changes**Base-case**Mean14,54111.114.414,62511,66416,37013,03716,69513,279**Cost of trastuzumab**Lower−30%9135728510,542839510,8848658−38%−38%−36%−36%−35%−35%Upper+30%20,11616,04322,19817,67822,50517,90138%38%36%36%35%35%**Effectiveness of trastuzumab**\
Disease-free survival HR\
12 m versus 0 mLower0.507496597410,338823212,0799610−49%−49%−37%−37%−28%−28%Upper0.7462,87350,39833,61826,77825,74020,464330%332%105%105%54%54%**Effectiveness of trastuzumab**\
Disease-free survival HR\
12 m versus 6 mLower1.2011,3779070−22%−22%Upper1.3619,92415,89936%36%**Effectiveness of trastuzuma**b\
Disease-free survival HR\
12 versus 9 mLower1.0914,52611,568−11%−11%Upper1.1818,16414,46511%11%**Age at start**Lower4014,68811.715.213,35210,63014,99411,92115,32212,1691%6%6%−9%−9%−8%−9%−8%−8%Upper5014,33610.413.516,42513,13018,30714,61118,61914,840−1%−7%−7%12%13%12%12%11%12%**Discount rate**\
for costsLower0%17,61213,49710,76415,48512,33215,96312,69821%−8%−8%−5%−5%−4%−4%Upper7%12,62415,31712,21616,93213,48417,17413,660−13%5%5%3%3%3%3%**Discount rate**\
for effectivenessLower0%18.423.973355791828365348499669966%66%−50%−50%−49%−50%−49%−50%Upper7%7.810.125,34120,43128,08822,59928,45522,854−30%−30%73%75%72%73%70%72%Blank spaces indicate no effects on the results of the base-case scenario*LY* life-years, *M* month, *QALYs* quality-adjusted life-years, *HR* hazard ratio Fig. 4The impact of life expectancy on the probabilities of being cost effective among different treatment strategies. Max age threshold represents the maximum patient age at onset of treatment that, for those patients, strategy remains optimal at a particular WTP threshold, *WTP* willingness-to-pay, *GDP* gross domestic product

Figure [5](#Fig5){ref-type="fig"} illustrates the effect of price reductions on the maximum age threshold. Our analyses revealed that trastuzumab is only cost effective if the price was to be reduced by 30%; however, this reduction would make 1 year of trastuzumab use the optimal strategy only if it was given to patients younger than 49.5 years of age. As Fig. [5](#Fig5){ref-type="fig"} shows, a 10% reduction in price increases the maximum age threshold by 3 and 6 years for the 6-month and 1-year treatment regimens, respectively.Fig. 5The impact of price reduction on max-age threshold at WTP 3×GDP in Iran. *WTP* willingness-to-pay, *GDP* gross domestic product, *max-age* maximum age

The internal validation results for the three strategies, including no trastuzumab and 1 year and 6 months of trastuzumab use revealed no significant differences between the results of the model and the results of the trials used to perform this study (Table [5](#Tab5){ref-type="table"}).Table 5Results of the internal validationNo trastuzumab  (HERA trial versus model)6 months of trastuzumab  (PHARE trial versus model)1 year of trastuzumab  (HERA trial versus model)Overall survival*p* = 0.489*p* = 0.388*p* = 0.424Disease-free survival*p* = 0.395*p* = 0.319*p* = 0.267

Discussion {#Sec16}
==========

The use of monoclonal antibodies such as trastuzumab is a hotly debated topic among policymakers, patients, and healthcare professionals in MICs due to their considerable impact on the healthcare budgets of these nations. For example, in Iran, trastuzumab alone accounts for approximately €93--140 million (approximately 4--6%) of total pharmaceutical expenditure \[[@CR1]\]. Trastuzumab is an effective but very expensive drug for patients with HER2-positive BC; therefore, policymakers in MICs can neither ignore it because of its effectiveness nor reimburse it with the same duration, as clinical guidelines have recommended in high-income countries (HICs), due to its cost. Specifically, more money spent on trastuzumab means less money for other treatments \[[@CR31]\]. The questions that healthcare professionals and policymakers in these countries must answer include: "What is the optimum duration of trastuzumab use to provide an efficient and affordable treatment?" and "How can we balance population health and affordability?" In response to these questions, our study provides valuable information regarding the cost effectiveness of various trastuzumab strategies in Iran, which may also be useful for other MICs. Moreover, to our knowledge this is the first CEA that examines age heterogeneity of patients and explores the impact of life expectancy on the cost effectiveness of various trastuzumab strategies in an MIC.

The effectiveness of shorter durations of trastuzumab therapy has been studied in various RCTs. The FinHER (Finland Herceptin) trial \[[@CR32]\] investigated clinical outcomes in 9 weeks of trastuzumab use and reported an HR of 0.42 (95% CI 0.21--0.83, *p* = 0.01) for the DFS of trastuzumab use versus no trastuzumab. However, this study was faced with some limitations, such as small sample size, and the results of other trials (SOLD \[[@CR33]\] and SHORT-HER \[[@CR34]\]) that also focused on 9-week trastuzumab use have not yet published. As a result, we therefore excluded the 9-week strategy as a comparator in this study. The clinical outcomes of 6 months of trastuzumab use were the subject of two RCTs (PHARE \[[@CR3]\] and PERSEPHONE \[[@CR35]\]). Since only the results of PHARE are currently available, we used the PHARE results in this study. Our assumption regarding the DFS HR in the 9-month strategy was not supported by a real RCT. It was therefore necessary to make assumptions to investigate a potentially cost-effective strategy between 6 months and 1 year of trastuzumab use. Finally, the model was internally validated based on the results of the aforementioned RCTs.

A previously published CEA reported that 1 year of trastuzumab use is not cost effective in Iran \[[@CR36]\]; however, this study had some methodological inconsistencies when assessed using the Drummond economic evaluation checklist \[[@CR37]\] and also used an inappropriate trastuzumab cost. The cost of 1 year of trastuzumab use by a 70-kg woman was estimated at \$48,850, which is inconsistent with the public price of trastuzumab dosage forms (€500 and €1294 for 150 and 440 mg vials, respectively \[€22,992\] \[[@CR38]\]). Consequently, it was necessary to conduct a new study using appropriate methods and more reliable input parameters. For this purpose, we attempted to design a standard economic evaluation using country-specific information, such as the results of a real-world cost analysis that exclusively investigated HER2-positive direct medical costs in Iran \[[@CR6]\].

Our results show that the most cost-effective strategy in the treatment of early HER2-positive BC in Iran is 6 months of trastuzumab as an adjuvant therapy. This strategy remains optimal, even if the price of trastuzumab is reduced by almost 30% (Online Resource 1). The 1-year strategy is only cost effective at higher WTP thresholds. Since, the 9-month strategy was dominated by the 6-month and 1-year strategies, from an efficiency perspective, the 6-month and 1-year strategies are the two best strategies. If the 6-month protocol is considered the standard of care, and doctors continue to adhere to this strategy, Iran can save €40 million/year compared with a 1-year trastuzumab strategy. It is worth noting that all these results can vary if the age of patients at the onset of treatment is changed, and that these various strategies for trastuzumab use would not be cost effective in patients older than 59 years of age (Fig. [4](#Fig4){ref-type="fig"}). In other words, in addition to a lower absolute WTP threshold for expensive drugs in MICs, life expectancy in these countries (e.g. 76.6 years for Iranian women) is also generally lower than in HICs. These two issues can affect the results of a CEA in MICs.

We compared our results with the results of model-based CEAs \[[@CR10], [@CR39]--[@CR42]\] in other countries that used the same study perspective (healthcare), time horizon (lifetime), and trastuzumab use duration (1 year). Two studies (in China \[[@CR39]\] and Belgium \[[@CR42]\]) calculated ICER values that were lower than those in our study (\$8041 and €10,315, respectively), while four CEAs (in the US \[[@CR40], [@CR41]\], Australia \[[@CR43]\], and the UK \[[@CR10]\]) estimated higher ICERs (\$39,982, \$26,417, \$A22,793, and £25,803, respectively). Regardless of this variation, in all studies, including our study, ICERs were primarily affected by the cost of trastuzumab. Despite the methodological similarities between this study and other studies, we cannot easily compare our results with other CEAs because of differences in various parameters, such as costs of trastuzumab, prices for healthcare services, discount rates, background mortality rates, and sources of estimation of the effectiveness of trastuzumab. On the other hand, a CEA in Colombia, using a shorter time horizon (20 years), concluded that trastuzumab is not cost effective, even though trastuzumab was cheaper (US\$4,219 versus €22,992) and advanced-stage treatment (downstream costs) was more costly (US\$52,093 versus €16,926) compared with costs in Iran \[[@CR44]\]. However, comparisons between that study and our study are difficult, not only because of differences in time horizon and cost components but also because of differences in the sources of clinical effectiveness and utility values that were used. This means that comparisons between CEAs of trastuzumab, and between MICs, are also prone to the same problems that arise when comparisons between CEAs in HICs are performed.

Our study faced four notable limitations. First, we had to use the results of studies performed in HICs due to the lack of country-specific health-related quality of life (HRQoL). In fact, there are no good-quality publications on HRQoL in Iran. However, this limitation has no major impact on the overall results since our one-way sensitivity analysis showed ±30% changes in utility values caused less than ±8% changes in the estimated ICER. Second, the HERA trial has recently reported 11 years of median follow-up, and data from this trial could have been used to update the parameter estimates in our model \[[@CR45]\]. However, the updated estimate of effectiveness of trastuzumab after 11 years was lower than the effectiveness after 2 years (i.e. an increase in the HR for DFS from 0.62 to 0.73). However, the results of one-way sensitivity analysis (Online Resource 2) that any reduced effectiveness of trastuzumab would not change the conclusion that the price of trastuzumab must be reduced significantly in order for it to have any chance of being cost effective, even for a subgroup of the patient population (i.e. younger patients). Third, the cost effectiveness of the 9-month strategy was estimated based on an assumption of effectiveness due to a lack of data. Despite its low impact on the overall results, as demonstrated by sensitivity analysis (Table [4](#Tab4){ref-type="table"}), our CEA can be updated when the results of the SOLD \[[@CR33]\] and/or SHORT-HER \[[@CR34]\] trials become available. Finally, while it is known that women with hormone receptor-negative tumors have an increased risk of recurrence and death, we did not examine the cost effectiveness of treatment decisions based on hormone receptor status \[[@CR46]\]. This is something that should be examined in the future.

New drugs launched in MICs do not necessarily have the same effectiveness or affordability as in HICs. Policymakers and other primary stakeholders, such as healthcare professionals and patient communities, should focus on a strategy that will help to create a balance between the highest attainable level of health and affordability of the new drug. However, if there is a desire to implement widely accepted clinical guidelines in MICs, concessions are unavoidable. There are four approaches that would lead to recommending 1 year of trastuzumab use in Iran: (1) price reduction; (2) use of a higher WTP threshold; (3) a combination of these two methods; and (4) 'watchful waiting' for a generic product. Our results showed that the first two options, either price reduction (by −30%) \[Fig. [3](#Fig3){ref-type="fig"}\] or the use of a higher WTP threshold (4 × GDP), cannot achieve a new balancing point between population health and affordability to switch to a longer course of trastuzumab therapy (Online Resource 3). The third option could be a potential solution; however, due to changes in the price of trastuzumab and the WTP threshold, the maximum age threshold for 1 year of trastuzumab use should be re-estimated. Moreover, the use of a higher WTP would set a precedent for other treatments. The 'watchful waiting' approach can indeed enhance affordability in MICs; however, this would mean waiting many years before drugs such as trastuzumab would be reimbursed in MICs. In many cases, 'watchful waiting' would mean a large amount of health loss. Therefore, a more equitable solution would involve revamping pharmaceutical pricing systems to make new drugs more affordable for lower income countries. For example, a 75% price reduction would be needed to make 1 year of trastuzumab, the strategy recommended in clinical guidelines in HICs, cost effective for all patients younger than 76.6 years (the average life expectancy) in Iran (Fig. [5](#Fig5){ref-type="fig"}).

Effectiveness and affordability are not the only two factors to consider when policymakers make reimbursement decisions. Other factors, such as budget impact and equity analysis, are also important to consider. In fact, using multicriteria decision analysis (MCDA) that includes various factors is likely the best way to help policymakers reach a satisfactory conclusion \[[@CR47]\].

Conclusions {#Sec17}
===========

Most clinical guidelines prepared in HICs have recommended 1 year of trastuzumab use due to the efficacy of the drug; however, this treatment strategy would not be an affordable recommendation in MICs due to the lower absolute value of the WTP threshold and the lower life expectancy compared with HICs. Our study showed that 6 months of trastuzumab use is the most cost effective option for the Iranian healthcare setting at a WTP threshold of 3 × GDP and a maximum age threshold of 59 years. Policymakers and other stakeholders in MICs must find the best way to balance population health and affordability of an expensive intervention.
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